Review
Clinical Neurology
Kyoung-Sae Na, Jae Myeong Kang, Seo-Eun Cho
Summary: The prevalence of DSM-5-defined mixed features in major depressive episodes (MDE) and manic/hypomanic episodes was found to be 11.6% and 26.8% respectively. The lowest prevalence of mixed features was observed in East Asian countries, ranging from 0-2.2%. Subgroup analysis did not identify any significant factors influencing the heterogeneity of prevalence rates.
JOURNAL OF AFFECTIVE DISORDERS
(2021)
Review
Neurosciences
Stefanos Pittas, Xenophon Theodoridis, Anna-Bettina Haidich, Panteleimon-Vasilios Bozikas, Georgios Papazisis
Summary: The study did not find significant improvement in bipolar depression symptoms, functioning, and quality of life with the adjunctive therapy of N-acetylcysteine. Further trials with improved design and sample sizes are needed for conclusive evidence.
PSYCHOPHARMACOLOGY
(2021)
Review
Clinical Neurology
Konstantinos N. Fountoulakis, Mauricio Tohen, Carlos A. Zarate Jr
Summary: The study systematically reviewed the efficacy of lithium in different phases of Bipolar disorder, finding that it is effective in acute mania and maintenance treatment, either as monotherapy or in combination with other agents. However, its efficacy for acute bipolar depression requires combination with specific agents, and its efficacy in preventing depressive episodes remains unclear.
EUROPEAN NEUROPSYCHOPHARMACOLOGY
(2022)
Review
Psychiatry
Alessandro Miola, Konstantinos N. Fountoulakis, Ross J. Baldessarini, Marin Veldic, Marco Solmi, Natalie Rasgon, Aysegul Ozerdem, Giulio Perugi, Mark A. Frye, Antonio Preti
Summary: This systematic review examines the definitions, prevalence, and clinical characteristics of rapid-cycling bipolar disorder (RC-BD). The results indicate that RC-BD has a high prevalence (22.3%-35.5% of BD cases) and is associated with inferior treatment response, suicide attempts, and unsatisfactory response to mood stabilizers. Factors such as childhood maltreatment, mixed features, female sex, and type-II BD also show associations with RC-BD.
JOURNAL OF PSYCHIATRIC RESEARCH
(2023)
Review
Psychology, Clinical
Cecilia Samame, Paula Durante, Brenda Cattaneo, Ivan Aprahamian, Sergio Strejilevich
Summary: Cognitive impairment is a major obstacle to functional recovery in bipolar disorder. Cognitive remediation (CR) is considered a promising treatment, but this review found that CR had limited effects on functional improvement in bipolar disorder patients. The current data do not support the inclusion of CR as a treatment recommendation in clinical practice guidelines for bipolar disorder management.
PSYCHOLOGICAL MEDICINE
(2023)
Review
Clinical Neurology
Domenico Sciortino, Alessandro Pigoni, Giuseppe Delvecchio, Eleonora Maggioni, Giandomenico Schiena, Paolo Brambilla
Summary: The results suggest that repeated Transcranial Magnetic Stimulation (rTMS) may improve cognitive symptoms in patients with Bipolar Disorder (BD) but shows limited efficacy in patients with Schizophrenia (SCZ). However, the conclusions are limited by the use of different rTMS protocols in the studies.
JOURNAL OF AFFECTIVE DISORDERS
(2021)
Review
Psychiatry
Francesco Bartoli, Daniele Cavaleri, Bianca Bachi, Federico Moretti, Ilaria Riboldi, Cristina Crocamo, Giuseppe Carra
Summary: The study examined the efficacy and safety of repurposed drugs for bipolar disorder and found some drugs showing significant benefits in the short term, although with low quality of evidence. Despite some drugs showing superiority to placebo in treating bipolar depression, the evidence quality remains limited.
JOURNAL OF PSYCHIATRIC RESEARCH
(2021)
Article
Chemistry, Medicinal
Zheng Wang, Danhua Zhang, Yanli Du, Yin Wang, Tingting Huang, Chee H. H. Ng, Huimin Huang, Yanmeng Pan, Jianbo Lai, Shaohua Hu
Summary: The effectiveness of pharmacotherapy for bipolar depression with mixed features defined by DSM-5 is currently unclear in clinical treatment guidelines. This study evaluated the efficacy of quetiapine monotherapy and compared combination therapies of quetiapine plus valproate or lithium in patients who responded insufficiently to quetiapine alone. The results showed that quetiapine monotherapy appeared to be effective, and combining with either valproate or lithium had positive effects for insufficient responders.
Article
Neurosciences
Antimo Natale, Ludovico Mineo, Laura Fusar-Poli, Andrea Aguglia, Alessandro Rodolico, Massimo Tusconi, Andrea Amerio, Gianluca Serafini, Mario Amore, Eugenio Aguglia
Summary: This review summarizes the evidence on mixed states and mixed depression, highlighting the controversy and challenges in this field. It also emphasizes the need for further research to assist clinicians in managing mixed depression.
Review
Psychiatry
Lauro Estivalete Marchionatti, Thyago Antonelli-Salgado, Isadora Nunes Erthal, Savio Luiz Santos Lopes, Luiza Silveira Lucas, Diego Barreto Reboucas, Ives Cavalcante Passos
Summary: This systematic review on the impact of disease progression in the treatment of bipolar disorder patients found that efficacy decreases with clinical progression, supporting early intervention. However, tailored recommendations cannot be made based on disease stages currently, highlighting the need for further research.
PSYCHIATRY RESEARCH
(2022)
Review
Clinical Neurology
Anastasiya Nestsiarovich, Christopher E. S. Gaudiot, Ross J. Baldessarini, Eduard Vieta, Yiliang Zhu, Mauricio Tohen
Summary: This study examined the efficacy of maintenance pharmacotherapy for bipolar disorder by analyzing data from high-quality randomized controlled trials. The findings suggest that psychotropic monotherapy, including lithium, mood stabilizing anticonvulsants, and second generation antipsychotics, is more effective in preventing new episodes of BD compared to placebo. Additionally, specific drugs such as aripiprazole, asenapine, lithium, olanzapine, quetiapine, and risperidone long-acting showed significantly lower risk of new BD episodes.
EUROPEAN NEUROPSYCHOPHARMACOLOGY
(2022)
Article
Neurosciences
Diego Freitas Tavares, Paulo Suen, Carla Garcia Rodrigues dos Santos, Doris Hupfeld Moreno, Leandro Da Costa Lane Valiengo, Izio Klein, Lucas Borrione, Pamela Marques Forte, Andre R. Brunoni, Ricardo Alberto Moreno
Summary: Bilateral TBS targeting the DLPFC did not show significant efficacy as an add-on treatment for acute bipolar and unipolar mixed depression within a short period of time, with no significant differences observed compared to sham TBS.
NEUROPSYCHOPHARMACOLOGY
(2021)
Review
Neurosciences
Delfina Janiri, Lorenzo Moccia, Silvia Montanari, Valentina Zani, Claudia Prinari, Laura Monti, Daniela Chieffo, Marianna Mazza, Alessio Simonetti, Georgios D. D. Kotzalidis, Luigi Janiri
Summary: This review investigates the use of lithium in pediatric bipolar disorder (BD) and other externalizing childhood-related disorders. The results suggest that lithium is an efficacious and generally well-tolerated treatment in pediatric BD and conduct disorder (CD), but the evidence is limited due to the paucity of available data.
CURRENT NEUROPHARMACOLOGY
(2023)
Review
Clinical Neurology
Tien-Wei Hsu, Che-Sheng Chu, Pao-Yuan Ching, Guan-Wei Chen, Chih-Chuan Pan
Summary: This study conducted a systematic review and meta-analysis to evaluate the antidepressant effects of memantine in patients with major mental diseases. The results showed that memantine effectively alleviates depressive symptoms in patients with mood disorders with a small effect size, but it does not have a significant effect in patients with schizophrenia.
JOURNAL OF AFFECTIVE DISORDERS
(2022)
Review
Clinical Neurology
Carina Winkler S. orensen, Charlotte Sonne, Maria Sacha, Maria Kristiansen, Sigrid Zeuthen Hannemose, Dan J. Stein, Jessica Carlsson
Summary: Most randomized controlled trials of mood and anxiety disorders rely on quantitative methods alone. However, supplementing quantitative data with qualitative methods can offer additional insights. This systematic review examined RCTs that used mixed-method approaches to explore participants' perspectives, identifying the number of such studies, describing their characteristics, and highlighting the potential advantages of this approach.
JOURNAL OF AFFECTIVE DISORDERS
(2023)
Review
Clinical Neurology
Xenia Gonda, Peter Dome, Joanna C. Neill, Frank Tarazi
Summary: The treatment of major depressive disorder (MDD) and treatment-resistant depression (TRD) is still a major unmet need. Current drugs have limited efficacy or undesirable side effects. Developing novel antidepressant drugs beyond the monoamine targets may be an effective strategy to improve the treatment of MDD and TRD.
Article
Psychiatry
Jerome Sarris, Arun Ravindran, Lakshmi N. Yatham, Wolfgang Marx, Julia J. Rucklidge, Roger S. McIntyre, Shahin Akhondzadeh, Francesco Benedetti, Constanza Caneo, Holger Cramer, Lachlan Cribb, Michael de Manincor, Olivia Dean, Andrea Camaz Deslandes, Marlene P. Freeman, Bangalore Gangadhar, Brian H. Harvey, Siegfried Kasper, James Lake, Adrian Lopresti, Lin Lu, Najwa-Joelle Metri, David Mischoulon, Chee H. Ng, Daisuke Nishi, Roja Rahimi, Soraya Seedat, Justin Sinclair, Kuan-Pin Su, Zhang-Jin Zhang, Michael Berk
Summary: The study aimed to provide definitive evidence-informed clinical guidelines for the use of nutrient-based 'nutraceuticals' and plant-based 'phytoceuticals' in treating major psychiatric disorders. These guidelines were developed by an international task force involving leading experts from 15 countries to assist clinicians in making informed decisions.
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY
(2022)
Review
Clinical Neurology
Gerard Anmella, Maria Faurholt-Jepsen, Diego Hidalgo-Mazzei, Joaquim Radua, Ives C. Passos, Flavio Kapczinski, Luciano Minuzzi, Martin Alda, Sandra Meier, Tomas Hajek, Pedro Ballester, Boris Birmaher, Danella Hafeman, Tina Goldstein, Elisa Brietzke, Anne Duffy, Benno Haarman, Carlos Lopez-Jaramillo, Lakshmi N. Yatham, Raymond W. Lam, Erkki Isometsa, Rodrigo Mansur, Roger S. McIntyre, Benson Mwangi, Eduard Vieta, Lars Vedel Kessing
Summary: This study examined the effectiveness of smartphone-based interventions for bipolar disorder (BD) and how the included studies reported user-engagement indicators. The results showed no evidence to support the reduction of depressive or manic symptoms in BD through smartphone interventions. The high heterogeneity among studies suggests the need for expert consensus and the use of more sensitive outcomes in future research.
Review
Psychiatry
Smadar V. Tourjman, Gabriella Buck, Didier Jutras-Aswad, Atul Khullar, Shane McInerney, Gayatri Saraf, Jairo V. Pinto, Stephane Potvin, Marie-Josee Poulin, Benicio N. Frey, Sidney H. Kennedy, Raymond W. Lam, Glenda MacQueen, Roumen Milev, Sagar V. Parikh, Arun Ravindran, Roger S. McIntyre, Ayal Schaffer, Valerie H. Taylor, Michael van Ameringen, Lakshmi N. Yatham, Serge Beaulieu
Summary: This task force report examines the association between cannabis use and bipolar disorder, major depressive disorder, and comorbid cannabis use disorder. The results indicate that cannabis use is associated with worsened course and functioning of both mood disorders, particularly in bipolar disorder. However, the treatment of comorbid cannabis use disorder and major depressive disorder did not show significant results.
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE
(2023)
Letter
Psychiatry
Calypso A. Mitkani, Thomas T. Tegos, Vasilios K. Kimiskidis, Konstantinos N. Fountoulakis
PSYCHIATRY RESEARCH
(2022)
Article
Psychiatry
Felicia Iftene, Roumen Milev, Adriana Farcas, Scott Squires, Daria Smirnova, Konstantinos N. Fountoulakis
Summary: This study investigated the rate of clinical depression in the adult population during the COVID-19 pandemic, as well as changes in anxiety, distress, and suicidal ideation. The study found that Canadians had a higher rate of depression, distress, and suicidal ideation compared to the worldwide population, but the relative risk of developing depression with a history of mental disorders was lower.
FRONTIERS IN PSYCHIATRY
(2022)
Article
Public, Environmental & Occupational Health
Jelena Vrublevska, Viktorija Perepjolkina, Kristine Martinsone, Jelena Kolesnikova, Ilona Krone, Daria Smirnova, Konstantinos N. Fountoulakis, Elmars Rancans
Summary: This study examined the association of various sociopsychological and health-related factors with anxiety in the general population during the COVID-19 state of emergency, and identified predictive factors for anxiety.
FRONTIERS IN PUBLIC HEALTH
(2022)
Review
Psychiatry
Joshua D. Rosenblat, M. Ishrat Husain, Yena Lee, Roger S. McIntyre, Rodrigo B. Mansur, David Castle, Hilary Offman, Sagar Parikh, Benicio N. Frey, Ayal Schaffer, Kyle T. Greenwaym, Nicolas Garel, Serge Beaulieu, Sidney H. Kennedy, Raymond W. Lam, Roumen Milev, Arun Ravindran, Valerie Tourjman, Michael Van Ameringen, Lakshmi N. Yatham, Valerie Taylor
Summary: There is currently only low-level evidence to support the efficacy and safety of psychedelics for major depressive disorder.
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE
(2023)
Article
Psychiatry
Laura B. Jones, Melissa Vereschagin, Angel Y. Wang, Richard J. Munthali, Julia Pei, Chris G. Richardson, Priyanka Halli, Hui Xie, Brian Rush, Lakshmi Yatham, Anne M. Gadermann, Krishna Pendakur, Ana Paula Prescivalli, Lonna Munro, Ronny Bruffaerts, Randy P. Auerbach, Philippe Mortier, Daniel V. Vigo
Summary: This study aimed to examine time trends in suicidal ideation among post-secondary students in Canada over the first three waves of the COVID-19 pandemic and identify subpopulations at increased risk. While the general university student population showed relative resilience in terms of suicidal ideation, specific subpopulations, such as Chinese students or other non-Indigenous ethnic minorities, experienced higher risk factors related to suicidal ideation during the pandemic. Further monitoring and targeted support for at-risk subpopulations should be considered to address potential delayed impacts.
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE
(2023)
Article
Biochemistry & Molecular Biology
Ruiyang Ge, Roberto Sassi, Lakshmi N. N. Yatham, Sophia Frangou
Summary: This study classified mood and anxiety disorders in youth aged 9-10 years into three subtypes using multimodal neuroimaging data. These subtypes showed differences in brain development and functioning, and were closely associated with family conflict and social adversity.
MOLECULAR PSYCHIATRY
(2023)
Review
Clinical Neurology
Eva-Maria Tsapakis, Calypso A. A. Mitkani, Konstantinos N. N. Fountoulakis
Summary: Neurological soft signs are possible indicators of abnormal neurodevelopment and neural connectivity. They are not exclusive to schizophrenia, but they appear to be a trait characteristic in psychosis and can serve as an objective measure for serious psychiatric disorder assessment. Neurocognitive deficits may contribute to the construct of NSS, and they may help identify individuals at risk of developing schizophrenia later in life.
Article
Psychiatry
Konstantinos N. Fountoulakis, Grigorios N. Karakatsoulis, Seri Abraham, Kristina Adorjan, Helal Uddin Ahmed, Renato D. Alarcon, Kiyomi Arai, Sani Salihu Auwal, Julio Bobes, Teresa Bobes-Bascaran, Julie Bourgin-Duchesnay, Cristina Ana Bredicean, Laurynas Bukelskis, Akaki Burkadze, Indira Indiana Cabrera Abud, Ruby Castilla-Puentes, Marcelo Cetkovich, Hector Colon-Rivera, Ricardo Corral, Carla Cortez-Vergara, Piirika Crepin, Domenico de Berardis, Sergio Zamora Delgado, David de Lucena, Avinash de Sousa, Ramona di Stefano, Seetal Dodd, Livia Priyanka Elek, Anna Elissa, Berta Erdelyi-Hamza, Gamze Erzin, Martin J. Etchevers, Peter Falkai, Adriana Farcas, Ilya Fedotov, Viktoriia Filatova, Nikolaos K. Fountoulakis, Iryna Frankova, Francesco Franza, Pedro Frias, Tatiana Galako, Cristian J. Garay, Leticia Garcia-Alvarez, Paz Garcia-Portilla, Xenia Gonda, Tomasz M. Gondek, Daniela Morera Gonzalez, Hilary Gould, Paolo Grandinetti, Arturo Grau, Violeta Groudeva, Michal Hagin, Takayuki Harada, Tasdik M. Hasan, Nurul Azreen Hashim, Jan Hilbig, Sahadat Hossain, Rossitza Iakimova, Mona Ibrahim, Felicia Iftene, Yulia Ignatenko, Matias Irarrazaval, Zaliha Ismail, Jamila Ismayilova, Asaf Jacobs, Miro Jakovljevic, Nenad Jaksic, Afzal Javed, Helin Yilmaz Kafali, Sagar Karia, Olga Kazakova, Doaa Khalifa, Olena Khaustova, Steve Koh, Svetlana Kopishinskaia, Korneliia Kosenko, Sotirios A. Koupidis, Illes Kovacs, Barbara Kulig, Alisha Lalljee, Justine Liewig, Abdul Majid, Evgeniia Malashonkova, Khamelia Malik, Najma Iqbal Malik, Gulay Mammadzada, Bilvesh Mandalia, Donatella Marazziti, Darko Marcinko, Stephanie Martinez, Eimantas Matiekus, Gabriela Mejia, Roha Saeed Memon, Xarah Elenne Meza Martinez, Dalia Mickeviciute, Roumen Milev, Muftau Mohammed, Alejandro Molina-Lopez, Petr Morozov, Nuru Suleiman Muhammad, Filip Mustac, Mika S. Naor, Amira Nassieb, Alvydas Navickas, Tarek Okasha, Milena Pandova, Anca-Livia Panfil, Liliya Panteleeva, Ion Papava, Mikaella E. Patsali, Alexey Pavlichenko, Bojana Pejuskovic, Mariana Pinto da Costa, Mikhail Popkov, Dina Popovic, Nor Jannah Nasution Raduan, Francisca Vargas Ramirez, Elmars Rancans, Salmi Razali, Federico Rebok, Anna Rewekant, Elena Ninoska Reyes Flores, Maria Teresa Rivera-Encinas, Pilar A. Saiz, Manuel Sanchez de Carmona, David Saucedo Martinez, Jo Anne Saw, Goerkem Saygili, Patricia Schneidereit, Bhumika Shah, Tomohiro Shirasaka, Ketevan Silagadze, Satti Sitanggang, Oleg Skugarevsky, Anna Spikina, Sridevi Sira Mahalingappa, Maria Stoyanova, Anna Szczegielniak, Simona Claudia Tamasan, Giuseppe Tavormina, Maurilio Giuseppe Maria Tavormina, Pavlos N. Theodorakis, Mauricio Tohen, Eva-Maria Tsapakis, Dina Tukhvatullina, Irfan Ullah, Ratnaraj Vaidya, Johann M. Vega-Dienstmaier, Jelena Vrublevska, Olivera Vukovic, Olga Vysotska, Natalia Widiasih, Anna Yashikhina, Panagiotis E. Prezerakos, Michael Berk, Sarah Levaj, Daria Smirnova
Summary: The current study aimed to investigate the rates of anxiety, clinical depression, and suicidality and their changes in health professionals during the COVID-19 outbreak. The study found a clinical depression rate of 13.16%, with male doctors and 'non-binary genders' having the lowest rates and 'non-binary gender' nurses and administrative staff having the highest rates. The study also highlighted a deterioration in mental state, family dynamics, and everyday lifestyle for some participants.
SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY
(2023)
Article
Psychiatry
Jairo Vinicius Pinto, Jose Alexandre S. Crippa, Keila Maria Cereser, Mireia Fortes Vianna-Sulzbach, erico de Moura Silveira Jr, Gabriel Santana da Rosa, Manoella Guatimuzim Testa da Silva, Gabriel Henrique Hizo, Leonardo Simao Medeiros, Carlos Eduardo Santana de Oliveira, Giovana Bristot, Alline Cristina Campos, Francisco Silveira Guimaraes, Jaime E. C. Hallak, Antonio W. Zuardi, Lakshmi N. Yatham, Flavio Kapczinski, Marcia Kauer-Sant'Anna
Summary: The study aimed to test the efficacy of cannabidiol as an adjunctive treatment for bipolar depression. The results showed no significant difference between cannabidiol and placebo in the primary outcome, but exploratory analysis suggested some efficacy of cannabidiol in secondary outcomes. Further research with higher doses and better study designs is needed.
CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE
(2023)
Article
Clinical Neurology
Konstantinos N. Fountoulakis, Magdalini Ioannou, Mauricio Tohen, Bartholomeus C. M. Haarman, Carlos A. Zarate Jr
Summary: The treatment of bipolar depression remains challenging, with only a few FDA-approved medications available. This study investigated the pharmacodynamic properties of cariprazine and found that it aligns well with a previously developed model, suggesting a combination of effects on different receptors is necessary for effective treatment. The role of norepinephrine reuptake inhibition in cariprazine's mechanism of action requires further clarification.
EUROPEAN NEUROPSYCHOPHARMACOLOGY
(2023)
Review
Health Care Sciences & Services
Xenia Gonda, Gianluca Serafini, Peter Dome
Summary: The fight against suicide is challenging, as it is a complex and threatening psychiatric phenomenon. Despite advances in neurobiology research, identifying and predicting suicide remains a major challenge. Utilizing specific biological and genetic markers as intervention targets, such as the involvement of neuroinflammation, could provide a novel approach in the treatment of suicidal behavior.
JOURNAL OF PERSONALIZED MEDICINE
(2023)